Comparative effectiveness of tocilizumab vs standard care in patients with severe COVID-19-related pneumonia: a retrospective cohort study utilizing registry data as a synthetic control

BACKGROUND: The severity of coronavirus disease 2019 (COVID-19) infections has led to the development of several therapeutic agents, with tocilizumab becoming increasingly used to treat patients with COVID-19-related pneumonia. This study compared the use of tocilizumab treatment with the standard o...

Descripción completa

Detalles Bibliográficos
Autores principales: Uemura, Yukari, Ozaki, Ryoto, Shinozaki, Tomohiro, Ohtsu, Hiroshi, Shimizu, Yousuke, Izumi, Kazuo, Saito, Sho, Matsunaga, Nobuaki, Ohmagari, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694888/
http://dx.doi.org/10.1186/s12879-023-08840-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694888/
http://dx.doi.org/10.1186/s12879-023-08840-6

Ejemplares similares